BGPT: Paper Review: p53 biology and reactivation for improved therapy in MDS and AML

Explore by Goal

Quick Explanation Copied

Paper focus: p53 biology in MDS/AML and how “reactivating” wild-type p53—via mutant p53 reactivation or p53/MDM2/MDM4 axis inhibition—has produced mixed clinical outcomes, with key translational obstacles likely including tumor heterogeneity, TP53 allelic state, and biomarker stratification limits.

Long Explanation

p53 biology & reactivation for improved therapy in MDS/AML — rigorous paper critique

Review paper DOI: 10.1186/s40364-024-00579-9

This is a narrative synthesis of (i) how TP53 alterations arise within clonal hematopoiesis and progress to myeloid malignancy and (ii) how clinicians are attempting to restore p53 tumor-suppressive function using wild-type p53 reactivation (p53/MDM2/MDM4 axis inhibition) and mutant p53 reactivation (conformational correctors and related strategies), plus a mechanistic discussion of why clinical translation is hard.

Visual map: where “p53 reactivation” is trying to act

What this review claims (high level): TP53-altered clonal hematopoiesis contributes to inferior outcomes; therapeutic attempts focus on restoring p53 pathway activity either by inhibiting MDM2/MDM4 (for TP53-wt contexts) or by correcting/degrading mutant p53 (for TP53-mutant contexts).

Visual evidence: APR-246 (eprenetapopt) efficacy signals and where they break

The review reports multiple APR-246 studies (Phase I/II/III and combinations), including ORR/CR metrics and survival summaries, but notes that the field has inconsistent results and that at least one frontline Phase III trial did not meet its primary endpoint.

Critical read: these are reported response rates from trials as summarized by the review; cross-study comparisons are confounded by eligibility criteria (e.g., complex karyotype and mutation VAF summaries), design type (single-arm vs randomized), and endpoint definitions.

Visual evidence: Phase III frontline failure signal (as stated)

The review states that in a Phase III trial in TP53-mutated MDS (APR-246 + azacitidine vs azacitidine alone), the reported CR rate was higher in the combination arm, but the study failed to meet the primary endpoint and the difference did not reach statistical significance.

Mechanistic critique: why mutant-wild reactivation is plausibly hard

1) TP53 isn’t a single knob

The review emphasizes that clinical outcomes differ for TP53-mutated disease and that TP53 biology is complex (e.g., allele state, multi-hit events, complex cytogenetics), suggesting that a “reactivation” strategy may require precise patient selection.

2) Wild-type p53 reactivation depends on whether the pathway can execute

The review discusses that in TP53-wt tumors, p53 can be suppressed by MDM2/MDM4; hence MDM2/MDM4 inhibition is mechanistically reasonable. Yet, the cited clinical experience for MDM2 inhibitors in AML/MDS is described as delivering limited benefit with substantial toxicities (e.g., GI toxicity, myelosuppression leading to trial discontinuations or failure to meet primary endpoints).

3) Mutant p53 “reactivation” may be biology-dependent and not solely structural

The review highlights multiple mechanistic classes (electrophilic correctors such as APR-246/PRIMA-1MET; arsenic trioxide; and degradation strategies), and it notes that some compounds can also have mutant p53–independent effects, complicating attribution.

Evidence-table: trial summaries that the review provides (APR-246 focus)

Trial ID	Population (as described)	Reported metrics in review	Design/endpoint signal (as described)
NCT03588078	TP53-mutated MDS/AML; APR-246 + azacitidine	MDS ORR 62%, MDS CR 47%; AML ORR 33%, AML CR 17%; DoR MDS 10.4 mo; OS MDS 12.1 mo; OS AML 13.9 mo; 73% achieved TP53 VAF <5% among responders	Phase Ib/II; combination activity reported; median follow-up 9.7 mo
NCT03072043	TP53-mutated myeloid neoplasms; APR-246 + azacitidine	ORR 71% (ITT), CRR 44%; CR in MDS 50%; median OS 10.8 mo (reviewed as compared favorably to azacitidine alone)	Phase Ib/II; emphasizes favorable response metrics but cross-trial comparability limited
NCT03931291	Post-HSCT maintenance; APR-246 + azacitidine	RFS median 12.5 mo; OS median 20.6 mo (review summary); pre-HSCT mutant TP53 detected in 30; among relapse-free completers, detection status described	Phase II maintenance concept; safety described as acceptable in review
NCT03745716	Frontline TP53-mutated MDS; APR-246 + azacitidine vs azacitidine	CR rate 37% higher with combination, but not statistically significant (per review)	Phase III failed primary endpoint in review summary
NCT04214860	APR-246 + venetoclax + azacitidine in TP53-mutated myeloid malignancies	ORR 64%; CRR 38%; 26% achieved TP53 VAF <5% clearance among NGS-tested	Phase I dose-finding/expansion; safety acceptable in review summary

Interpretation caution: this table is only what the review explicitly reports; it is not a re-analysis of individual patient-level data.

Blind spots & counterpoints (epistemic humility)

Narrative review limits falsifiability: conclusions inherit publication bias and heterogeneity across trials; the review itself uses literature synthesis rather than new meta-analytic re-estimation.
Cross-trial heterogeneity: TP53 mutation spectrum, allelic state/LOH, karyotype complexity, baseline VAF, prior therapy, and endpoint definitions can differ substantially—weakening direct comparisons.
Mechanism-vs-clinical outcome mismatch: some agents have mutant p53–independent effects or act through multiple pathways; mechanistic plausibility does not guarantee clinical durability.

Where the review points the field next

The review’s open questions include whether predictive biomarker stratification (including conformation-specific antibodies / allele-state measures) can identify responders and whether combinations that block other drivers can enhance outcomes, especially given that single-pathway “reactivation” has yielded inconsistent clinical success.

Author reviews (BGPT links)

Feedback:

Updated: April 29, 2026